Literature DB >> 17645767

Antigen-induced B cell apoptosis is independent of complement C4.

K B Faust1, D Finke, K Klempt-Giessing, K Randers, B Zachrau, P Schlenke, H Kirchner, S Goerg.   

Abstract

Deficiencies in early complement components are associated with the development of systemic lupus erythematosus (SLE) and therefore early complement components have been proposed to influence B lymphocyte activation and tolerance induction. A defect in apoptosis is a potential mechanism for breaking of peripheral B cell tolerance, and we hypothesized that the lack of the early complement component C4 could initiate autoimmunity through a defect in peripheral B lymphocyte apoptosis. Previous studies have shown that injection of a high dose of soluble antigen, during an established primary immune response, induces massive apoptotic death in germinal centre B cells. Here, we tested if the antigen-induced apoptosis within germinal centres is influenced by early complement components by comparing complement C4-deficient mice with C57BL/6 wild-type mice. We demonstrate that after the application of a high dose of soluble antigen in wild-type mice, antibody levels declined temporarily but were restored almost completely after a week. However, after antigen-induced apoptosis, B cell memory was severely limited. Interestingly, no difference was observed between wild-type and complement C4-deficient animals in the number of apoptotic cells, restoration of antibody levels and memory response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17645767      PMCID: PMC2219293          DOI: 10.1111/j.1365-2249.2007.03456.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  The need for central and peripheral tolerance in the B cell repertoire.

Authors:  C C Goodnow; S Adelstein; A Basten
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

Review 2.  Immunological unresponsiveness.

Authors:  W O Weigle
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

Review 3.  Lupus diseases associated with hereditary and acquired deficiencies of complement.

Authors:  V Agnello
Journal:  Springer Semin Immunopathol       Date:  1986

4.  The role of complement receptor positive and complement receptor negative B cells in the primary and secondary immune response to thymus independent type 2 and thymus dependent antigens.

Authors:  T Lindsten; L J Yaffe; C B Thompson; G Guelde; A Berning; I Scher; J J Kenny
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

5.  Soluble antigen profoundly reduces memory B-cell numbers even when given after challenge immunization.

Authors:  G J Nossal; M Karvelas; B Pulendran
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

6.  Magnitude of response of histocompatibility-restricted T-cell clones is a function of the product of the concentrations of antigen and Ia molecules.

Authors:  L A Matis; L H Glimcher; W E Paul; R H Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

Review 7.  Complement deficiency: predisposing factor to autoimmune syndromes.

Authors:  J P Atkinson
Journal:  Clin Exp Rheumatol       Date:  1989 Sep-Oct       Impact factor: 4.473

8.  A form of immunologic tolerance through impairment of germinal center development.

Authors:  B Pulendran; M Karvelas; G J Nossal
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

9.  Impaired humoral immune response in complement C3-deficient guinea pigs: absence of secondary antibody response.

Authors:  E C Böttger; S Metzger; D Bitter-Suermann; G Stevenson; S Kleindienst; R Burger
Journal:  Eur J Immunol       Date:  1986-10       Impact factor: 5.532

10.  B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors.

Authors:  Robert A Barrington; Olga Pozdnyakova; Mohammad R Zafari; Christopher D Benjamin; Michael C Carroll
Journal:  J Exp Med       Date:  2002-11-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.